References
- Andrea T, Anette W (2001). Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolaryngol, 258, 83-8. https://doi.org/10.1007/s004050000303
- Bircan S, Candir O, Kapucoglu N, Baspinar S (2006). The expression of p63 in basal cell carcionomas and association with histological differentiation. J Cutan Pathol, 33, 293-8. https://doi.org/10.1111/j.0303-6987.2006.00436.x
- Buffa FM, Bentzen SM, Daley FM (2004). Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res, 10, 3745. https://doi.org/10.1158/1078-0432.CCR-03-0248
- Chen YK, Hsue SS, Lin LM (2003). Immunohistochemical demonstration of p63 in DMBA-induced hamster buccal pouch squamous cell carcinogenesis. Oral Dis, 9, 235-40. https://doi.org/10.1034/j.1601-0825.2003.02920.x
- Chen YK, Huse SS, Lin LM (2003). Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol, 28, 451-5. https://doi.org/10.1046/j.1365-2273.2003.00743.x
- Choi HR, Batsakis JG, Zhan F, et al (2002). Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol, 33, 158-64. https://doi.org/10.1053/hupa.2002.30722
- Coindre JM (2003). Immunohistochemistry in the diagnosis of soft tissue tumors. Histopathology, 43, 1-16. https://doi.org/10.1046/j.1365-2559.2003.01639.x
- Di Como CJ, Urist MJ, Babayan I, et al (2002). p63 expression profiles in human normal and tumor tissues. Clin Cancer Res, 8, 494-501.
- Faridoni-laurens L, Bosq J, Janot F (2001). P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63. Oncogene, 20, 5302-12. https://doi.org/10.1038/sj.onc.1204687
- Foschini MP, Gaiba A, Cocchi R (2004). Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch, 444, 332-9. https://doi.org/10.1007/s00428-003-0969-x
- Gath H, Brakenhoff R (1999). Minimal residual disease in head and neck cancer. Cancer Metastasis Rev, 18, 109-26. https://doi.org/10.1023/A:1006268621730
- Ivan D, Diwan AH, Prieto VG (2005). Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol, 18, 137-42. https://doi.org/10.1038/modpathol.3800263
- Jimenez FJ, Grichnik JM, Buchanan MD, Clark RE (1995). Immunohistochemical techniques in Mohs micrographic surgery: their potential use in the detection of neoplastic cells masked by inflammation. J Am Acad Dermatol, 32, 89-94. https://doi.org/10.1016/0190-9622(95)90190-6
- Kargi A, Gurel D, Tuna B (2007). The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. App Immunohistochemist Mol Morphol, 15, 415-20. https://doi.org/10.1097/PAI.0b013e31802fab75
- Kaufmann O, Fietze E, Mengs J, Dietel M (2001). Value of p63 and Cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol, 116, 823-30. https://doi.org/10.1309/21TW-2NDG-JRK4-PFJX
- Koga F, Kawakami S, Fujii Y (2003). Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res, 9, 5501-7.
- Kristiansen G, Fritzsche FR, Wassermann K, et al (2008). GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer, 99, 939-48. https://doi.org/10.1038/sj.bjc.6604614
- Levrero M, De Laurenzi V, Costanzo A, et al. (1999). Structure, function and regulation of p63 and p73. Cell Death Differ, 6, 1146-53. https://doi.org/10.1038/sj.cdd.4400624
- Moskaluk CA (2002). Standardization of Clinical Immunohistochemistry: why, how, and by whom? Am J Clin Pathol, 118, 669-71. https://doi.org/10.1309/KM95-6LVL-UNLB-R3RH
- Muzio LL, Santarelli A (2005). p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol, 36, 187-94. https://doi.org/10.1016/j.humpath.2004.12.003
- Muzio LL, Campisi G, Farina A, et al (2007). Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest, 25, 464-9. https://doi.org/10.1080/07357900701509387
- Nylander K, Coates PJ, Hall PA (2000). Characterization of the expression pattern of p63 and np63 in benign and malignant oral epithelial lesions. Int J Cancer, 87, 368-72. https://doi.org/10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.0.CO;2-J
- Pitiphat W, Diehl SR, Laskaris G, et al (2002). Factors associated with delay in the diagnosis of oral cancer. J Dent Res, 81, 192-7. https://doi.org/10.1177/154405910208100310
- Rassam MB, Al-Bashir NN, Al-Salihi AR, et al (1995). Heatstable alkaline phosphatase: A putative tumor marker of head and neck squamous cell carcinoma. Acta Oncol, 34, 49-52.
- Sayan BS, Sayan AE, Yang AL et al (2007). Cleavage of the transactivation inhibitory domain of p63 by caspases enhances apoptosis. PNAS, 104, 10871-6. https://doi.org/10.1073/pnas.0700761104
- Strong EW, Kasdorf H, Henk JM (1995). Squamous cell carcinoma of the head and neck. In: Prognostic factors in cancer. Eds. Hermanek P, Gospodarowicz MK, Henson DE, et al. Springer, Berlin Heidelberg New York pp 12-22.
- Yang A, Kagdah M, Wang Y, et al (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell, 2, 305-16. https://doi.org/10.1016/S1097-2765(00)80275-0